HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

EMD 534085

a kinesin-5 inhibitor; structure in first source

Also Known As:

EMD-534085; EMD534085

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - EMD 534085: 2

Experts

1.	Bahleda, R: 1 article (12/2013)
2.	Beier, F: 1 article (12/2013)
3.	Bourgier, C: 1 article (12/2013)
4.	Deutsch, E: 1 article (12/2013)
5.	Gazzah, A: 1 article (12/2013)
6.	Gomez-Roca, C: 1 article (12/2013)
7.	Hollebecque, A: 1 article (12/2013)
8.	Klevesath, M: 1 article (12/2013)
9.	Kroesser, S: 1 article (12/2013)
10.	Lacroix, L: 1 article (12/2013)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2013 - "A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma." 12/01/2013 - "This first-in-man, single-center, open-label, phase I dose-escalation study (3 + 3 design) investigated EMD 534085 safety, pharmacokinetics and antitumor activity in refractory solid tumors, Hodgkin's lymphoma, or non-Hodgkin's lymphoma. " 03/01/2010 - "The selected clinical candidate EMD 534085 caused strong growth inhibition in human tumor xenograft models using Colo 205 colon carcinoma cells at doses below 30mg/kg administered twice weekly without showing severe toxicity as determined by loss of body weight."
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/01/2013 - "This first-in-man, single-center, open-label, phase I dose-escalation study (3 + 3 design) investigated EMD 534085 safety, pharmacokinetics and antitumor activity in refractory solid tumors, Hodgkin's lymphoma, or non-Hodgkin's lymphoma. "
3.	Lymphoma (Lymphomas) 12/01/2013 - "A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma."
4.	Hodgkin Disease (Hodgkin's Disease) 12/01/2013 - "This first-in-man, single-center, open-label, phase I dose-escalation study (3 + 3 design) investigated EMD 534085 safety, pharmacokinetics and antitumor activity in refractory solid tumors, Hodgkin's lymphoma, or non-Hodgkin's lymphoma. "
5.	Carcinoma (Carcinomatosis) 03/01/2010 - "The selected clinical candidate EMD 534085 caused strong growth inhibition in human tumor xenograft models using Colo 205 colon carcinoma cells at doses below 30mg/kg administered twice weekly without showing severe toxicity as determined by loss of body weight."